NewLimit, a longevity biotech company co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in Series C funding. The company plans to use the funds to advance its research and development and prepare for its first drug candidate to enter human clinical trials next year.

Founders Fund led the investment.

This funding round was led by Founders Fund. New investors include Thrive Capital, Greenoaks, and Quiet Capital, while existing shareholders Kleiner Perkins and Eli Lilly Ventures also participated.

Age-Focused Reprogramming Therapy

NewLimit primarily develops biotechnology therapies related to aging, focusing on restoring cellular function affected by aging through age-related reprogramming. This funding will support the continued advancement of related research and development.

Human trials are planned to begin next year.

According to the company's current plan, its first drug candidate will enter human clinical trials next year. This means that the project will move from the early research stage to clinical validation for patients.

For biotechnology companies, entering human trials is usually a key milestone in the research and development process. Following this round of financing, the outside world will be watching NewLimit's clinical trial progress and when the first trial results will be released.